Comprehensive Risk Profile of Gastrointestinal and Extra Articular Comorbidities in Ehlers–Danlos Syndrome: A Propensity‐Matched Analysis of 118,256 Individuals
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70506 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2026. Written by Saqr Alsakarneh and 6 co-authors. Institution: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Ehlers-Danlos Syndrome, Gastrointestinal Diseases. Cited 4 times so far (Crossref); 47 references.
Abstract (original language)
Background
Ehlers–Danlos syndrome (EDS) comprises inherited connective tissue disorders characterised by joint hypermobility, skin hyperextensibility and tissue fragility. It links to systemic comorbidities, including gastrointestinal (GI) disorders, but hitherto large‐scale data remain limited. We aimed to evaluate the prevalence of GI, systemic and psychological comorbidities in EDS patients versus propensity score‐matched controls, using a comprehensive research network database.
Design
This was a retrospective, propensity‐matched analysis (2005–2023) utilising the TriNetX network. We identified EDS patients (excluding Marfan's syndrome). Propensity score matching (1:1) generated balanced cohorts for age, sex and baseline characteristics. Comorbidities were analysed via prevalence rates and odds ratios (ORs) with 95% confidence intervals (CIs).
Results
Matched cohorts included 59,128 pairs. Among GI disorders, gastroesophageal reflux disease was most common in EDS (18.4%, OR 1.5, 95% CI 1.4–1.5, p < 0.001), followed by constipation (12.4%, OR 1.8, 95% CI 1.7–1.9, p < 0.001), irritable bowel syndrome (7.3%, OR 2.6, 95% CI 2.5–2.8, p < 0.001) and gastroparesis (4.7%, OR 8.2, 95% CI 7.3–9.2, p < 0.001). Psychiatric conditions showed heightened prevalence of anxiety (26.1%, OR 1.8, 95% CI 1.7–1.8, p < 0.001) and depression (18.7%, OR 1.3, 95% CI 1.2–1.3, p < 0.001). Systemic comorbidities included postural orthostatic tachycardia syndrome (13.2%, OR 899.7, 95% CI 483.8–1673.0, p < 0.001), chronic pain (7.9%, OR 7.0, 95% CI 6.4–7.6, p < 0.001), migraines (19.7%, OR 2.5, 95% CI 2.4–2.6, p < 0.001) and fibromyalgia (9.5%, OR 1.7, 95% CI 1.6–1.8, p < 0.001).
Conclusion
EDS patients exhibit heightened risk for GI, systemic and psychological comorbidities, highlighting the importance of multidisciplinary approaches for effective management.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
- Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, Missouri, USA.
- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Bilbao, Spain.
- Queen Square Institute of Neurology, University College London, London, UK.
- Wingate Institute of Neurogastroenterology, Queen Mary University of London, London, UK.
ORCID profiles: Omar Al Ta'ani, James K Ruffle, Adam D Farmer
Cite
APA
Alsakarneh, S., Al Ta'ani, O., Madi, M. Y., Syn, W. K., Ruffle, J. K., Aziz, Q., & Farmer, A. D. (2026). Comprehensive Risk Profile of Gastrointestinal and Extra Articular Comorbidities in Ehlers–Danlos Syndrome: A Propensity‐Matched Analysis of 118,256 Individuals. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70506
Vancouver
Alsakarneh S, Al Ta'ani O, Madi MY, Syn WK, Ruffle JK, Aziz Q, et al. Comprehensive Risk Profile of Gastrointestinal and Extra Articular Comorbidities in Ehlers–Danlos Syndrome: A Propensity‐Matched Analysis of 118,256 Individuals. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70506
BibTeX
@article{Alsakarneh2026,
author = {Alsakarneh, Saqr and Al Ta'ani, Omar and Madi, Mahmoud Y and Syn, Wing-Kin and Ruffle, James K and Aziz, Qasim and Farmer, Adam D},
title = {Comprehensive Risk Profile of Gastrointestinal and Extra Articular Comorbidities in Ehlers–Danlos Syndrome: A Propensity‐Matched Analysis of 118,256 Individuals},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70506}
}
EUVIMED